A broad range of serious diseases involve chronic inflammation, which causes both pain and progressive damage. Xalud Therapeutics is developing a locally-delivered, non-viral gene therapy that is designed to harness the ability of interleukin-10 to regulate the immune system and restore homeostasis. The company’s lead indication is in osteoarthritis We spoke to Diem Nguyen, CEO of Xalud, about the role inteleukin-10 plays in regulating multiple pathways in the immune system, Xalud’s gene therapy, and the indications the company is pursuing.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
